Alzamend Neuro, Inc.ALZNNASDAQ
Loading
Book Value/Share Growth Recovery in ProgressRecovering
Percentile Rank19
Year-over-Year Change
Year-over-year book value per share growth
Latest
-49.01%
↓ 259% vs avg
Percentile
P19
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
30.81%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -49.01% |
| Q3 2025 | -70.08% |
| Q2 2025 | 50.67% |
| Q1 2025 | -43.47% |
| Q4 2024 | 169.80% |
| Q3 2024 | 58.22% |
| Q2 2024 | 36.51% |
| Q1 2024 | -44.31% |
| Q4 2023 | -2276.35% |
| Q3 2023 | -103.66% |
| Q2 2023 | -47.29% |
| Q1 2023 | -33.32% |
| Q4 2022 | -21.41% |
| Q3 2022 | -24.39% |
| Q2 2022 | 18.48% |
| Q1 2022 | -8.16% |
| Q4 2021 | -23.72% |
| Q3 2021 | 563.92% |
| Q2 2021 | 252.45% |
| Q1 2021 | 0.00% |
| Q4 2020 | 0.00% |
| Q3 2020 | -100.00% |
| Q2 2020 | 0.00% |
| Q1 2020 | -100.00% |
| Q4 2019 | 0.00% |
| Q3 2019 | 557.21% |
| Q2 2019 | 0.00% |
| Q1 2019 | -84.01% |
| Q4 2018 | 0.00% |
| Q3 2018 | -26.73% |
| Q2 2018 | 0.00% |
| Q1 2018 | 2982.43% |
| Q4 2017 | 0.00% |
| Q3 2017 | 92.14% |
| Q2 2017 | 0.00% |
| Q1 2017 | -555.27% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |